"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year. Tsvetta argues investors need to understand that many companies don't just produce medicine, but also medical supplies, which contributes to profits. She sees Abivax (ABVX) as an international outperformer and expects Eli Lilly (LLY) to make a comeback in the weight loss drug market. George Tsilis highlights example options trades in Eli Lilly and Johnson & Johnson (JNJ).